Weining Volinn

574 total citations
15 papers, 423 citations indexed

About

Weining Volinn is a scholar working on Urology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Weining Volinn has authored 15 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Urology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Weining Volinn's work include Urinary Bladder and Prostate Research (10 papers), Hormonal and reproductive studies (5 papers) and Prostate Cancer Diagnosis and Treatment (4 papers). Weining Volinn is often cited by papers focused on Urinary Bladder and Prostate Research (10 papers), Hormonal and reproductive studies (5 papers) and Prostate Cancer Diagnosis and Treatment (4 papers). Weining Volinn collaborates with scholars based in United States and South Korea. Weining Volinn's co-authors include Gary Hoel, Lawrence A. Hill, Leonard S. Marks, Marc Gittelman, Herbert Lepor, Claus G. Roehrborn, Steven A. Kaplan, Scott MacDiarmid, Kim E. Caramelli and David Staskin and has published in prestigious journals such as Blood, Cancer Research and The Journal of Urology.

In The Last Decade

Weining Volinn

15 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weining Volinn United States 9 359 163 163 142 67 15 423
Christian P. Schmidbauer Austria 8 319 0.9× 181 1.1× 140 0.9× 200 1.4× 27 0.4× 10 417
Huilei Yan China 9 174 0.5× 122 0.7× 106 0.7× 68 0.5× 88 1.3× 18 326
Johnny Roy United States 7 464 1.3× 190 1.2× 220 1.3× 310 2.2× 69 1.0× 8 571
K J Hoefner United States 3 624 1.7× 275 1.7× 265 1.6× 461 3.2× 76 1.1× 4 737
Aare Mehik Finland 10 498 1.4× 315 1.9× 122 0.7× 230 1.6× 198 3.0× 17 640
R Fourcade France 7 240 0.7× 123 0.8× 85 0.5× 204 1.4× 20 0.3× 16 325
F Boeminghaus Germany 6 266 0.7× 113 0.7× 112 0.7× 118 0.8× 19 0.3× 17 340
M. Cemil Uygur Türkiye 13 267 0.7× 114 0.7× 98 0.6× 133 0.9× 28 0.4× 35 454
Süleyman Bulut Türkiye 10 126 0.4× 71 0.4× 54 0.3× 121 0.9× 24 0.4× 30 301
Allam Fakhoury United States 8 427 1.2× 321 2.0× 83 0.5× 116 0.8× 14 0.2× 10 453

Countries citing papers authored by Weining Volinn

Since Specialization
Citations

This map shows the geographic impact of Weining Volinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weining Volinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weining Volinn more than expected).

Fields of papers citing papers by Weining Volinn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weining Volinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weining Volinn. The network helps show where Weining Volinn may publish in the future.

Co-authorship network of co-authors of Weining Volinn

This figure shows the co-authorship network connecting the top 25 collaborators of Weining Volinn. A scholar is included among the top collaborators of Weining Volinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weining Volinn. Weining Volinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Sommerhalder, David, et al.. (2022). Abstract CT242: KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation. Cancer Research. 82(12_Supplement). CT242–CT242. 3 indexed citations
2.
O’Connor, Owen A., Enrica Marchi, Weining Volinn, et al.. (2018). Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. JNCI Cancer Spectrum. 2(4). pky038–pky038. 14 indexed citations
3.
O’Connor, Owen A., Enrica Marchi, Weining Volinn, & Won Seog Kim. (2016). Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate. Blood. 128(22). 4149–4149. 4 indexed citations
4.
Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2012). Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies. The Journal of Urology. 189(1S). S122–8. 92 indexed citations
5.
6.
Roehrborn, Claus G., Steven A. Kaplan, Herbert Lepor, & Weining Volinn. (2010). Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer and Prostatic Diseases. 14(2). 143–148. 51 indexed citations
7.
MacDiarmid, Scott, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2010). Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective α1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men. Urology. 75(3). 520–525. 26 indexed citations
8.
Morganroth, Joel, Herbert Lepor, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2010). Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled Study. Clinical Pharmacology & Therapeutics. 87(5). 609–613. 19 indexed citations
9.
10.
Gittelman, Marc, Leonard S. Marks, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2010). Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies. Research and Reports in Urology. Volume 3. 1–5. 2 indexed citations
11.
Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2009). RAPID RESPONSE OF IRRITATIVE AND OBSTRUCTIVE URINARY SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA TO TREATMENT WITH SILODOSIN IN 2 RANDOMIZED STUDIES. The Journal of Urology. 181(4). 694–694. 1 indexed citations
12.
Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2009). Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month, Open-label Extension Study. Urology. 74(6). 1318–1322. 56 indexed citations
13.
Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2009). Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies. The Journal of Urology. 181(6). 2634–2640. 110 indexed citations
14.
Cartwright, Patrick C., et al.. (2009). Efficacy and Safety of Transdermal and Oral Oxybutynin in Children With Neurogenic Detrusor Overactivity. The Journal of Urology. 182(4). 1548–1554. 22 indexed citations
15.
Caramelli, Kim E., David Staskin, & Weining Volinn. (2008). STEADY-STATE PHARMACOKINETICS OF AN INVESTIGATIONAL OXYBUTYNIN TOPICAL GEL IN COMPARISON WITH OXYBUTYNIN TRANSDERMAL SYSTEM. The Journal of Urology. 179(4S). 513–514. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian P. Schmidbauer Breakdown of academic impact, for papers by Huilei Yan Breakdown of academic impact, for papers by Johnny Roy Breakdown of academic impact, for papers by K J Hoefner Breakdown of academic impact, for papers by Aare Mehik Breakdown of academic impact, for papers by R Fourcade Breakdown of academic impact, for papers by F Boeminghaus Breakdown of academic impact, for papers by M. Cemil Uygur Breakdown of academic impact, for papers by Süleyman Bulut Breakdown of academic impact, for papers by Allam Fakhoury
Rankless by CCL
2026